The proportion of patients with clinical stage IA lung adenocarcinoma in the EGFR + /TP53 + group was significantly lower than those in the EGFR + /TP53- and EGFR-/TP53- groups. This evidence concerns the gene EGFR and lung adenocarcinoma.